Prometa Pharmacotherapy for Methamphetamine Dependence

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Walter Ling, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT00260481
First received: November 29, 2005
Last updated: January 28, 2013
Last verified: January 2013
  Purpose

The purpose of this study is to assess the efficacy of the PROMETA pharmacotherapy compared to placebo for initiating abstinence and for preventing relapse to methamphetamine use in treatment-seeking individuals meeting criteria for methamphetamine abuse. It is hypothesized that individuals assigned to receive the PROMETA pharmacotherapy, compared to placebo, will demonstrate significantly fewer and less intense withdrawal symptoms, more days abstinent from methamphetamine use, and fewer relapses to methamphetamine use as assessed by self-report of drug use verified by urine samples.


Condition Intervention Phase
Drug Abuse
Drug Dependence
Drug: Prometa
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-Blind, Placebo Controlled Trial of Prometa Pharmacotherapy for the Treatment of Methamphetamine Abuse

Resource links provided by NLM:


Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • Abstinence across the duration of the study [ Time Frame: from screening to termination ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Days of methamphetamine use [ Time Frame: from screening to termination ] [ Designated as safety issue: No ]
  • days of other drug use [ Time Frame: from screening to termination ] [ Designated as safety issue: No ]
  • cognitive functioning [ Time Frame: comparison of pre- to post-treatment scores ] [ Designated as safety issue: No ]

Enrollment: 120
Study Start Date: January 2006
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Prometa
    Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
Detailed Description:

Using a double-blind placebo design, the effectiveness of the Prometa protocol for methamphetamine dependence will be investigated as compared to a placebo condition. The procedure utilizes a combination of medications delivered both orally and by infusion in a controlled medical setting. Participants will be randomly assigned to the active medication or placebo condition, and will receive medications for 40 days, including two inpatient hospitalization phases of three days each. All participants will also receive once-weekly psychosocial cognitive-behavioral therapy throughout the 106 day study duration. A variety of data will be collected throughout the study, including psychological, cognitive, medical, and laboratory assessments.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be at least 18 years-of-age;
  • Have a DSM-IV-TR diagnosis of methamphetamine abuse or dependence as determined by SCID;
  • Be seeking treatment for methamphetamine abuse or dependence;
  • Be able to understand, and having understood, provide written informed consent;
  • If female and of child bearing potential, agree to use an approved method of birth control or be surgically sterile;
  • Have completed all other psychological assessments; -Have used methamphetamine at least 4 of the last 30 days. -

Exclusion Criteria:

  • Have current dependence, defined by DSM-IV-TR criteria, on any psychoactive substance other than methamphetamine, alcohol, nicotine, or marijuana or physiological dependence on alcohol requiring medical detoxification (CIWA-AR score ≥ 15);
  • Be mandated by the court to obtain treatment for methamphetamine-abuse or dependence;
  • Be anyone who, in the opinion of the investigator, would not be expected to complete the study protocol due to probable incarceration or relocation from the clinic area;
  • Have a current or previous psychiatric, or a neurological disorder including but not limited to epilepsy and absence seizures, fainting spells, brain disease, dementia, or any disorder that, in the opinion of the study physician requires ongoing treatment that would make study participation unsafe or which would make treatment compliance difficult.
  • Have a psychiatric disorder, as assessed by the SCID, or a neurological disorder including but not limited to epilepsy and absence seizures, brain disease, dementia or any disorder that, in the opinion of the study physician, requires ongoing treatment that would make study participation unsafe or which would make treatment compliance difficult;
  • Have had electroconvulsive therapy within the past 3 months preceding screening; Have current suicidal ideation or plan (within the past 30 days) as assessed by the SCID;
  • Be pregnant or lactating;
  • Have serious medical illnesses (including, but not limited to: uncontrolled hypertension, significant heart disease including myocardial infarction within one year of enrollment, or any clinically significant cardiovascular abnormality (ECG), hepatic, renal or gastrointestinal disorders that could result in a clinically significant alteration of metabolism or excretion of the study agent, potentially life-threatening or progressive medical illness other than addiction that may compromise subject safety or study conduct);
  • Have clinically significant abnormal laboratory values;
  • Benzodiazepine and/or similar sedative-hypnotic or anxiolytic use or abuse within 15 days of potential PROMETA Treatment;
  • Must not be habituated to benzodiazepines and must provide a urine sample that is negative for benzodiazepines;
  • Must not be taking supra-therapeutic doses of zolpidem (Ambien TM) or zaleplon (Sonata TM); Taking clonazepam (Klonopin TM) or other benzodiazepine;
  • Patients must not be taking cyclic antidepressants, lithium, methylxanthines, isoniazid, propoxyphene, monoamine oxidase inhibitors, buproprion HCL, and cyclosporine.
  • Have AIDS;
  • Have active tuberculosis (positive tuberculin test and confirmatory diagnostic chest x-ray);
  • Have known or suspected hypersensitivity to PROMETA;
  • Have been treated with PROMETA for any reason currently or during the past year;
  • Have any disorder or condition that, in the opinion of the study physician, would make study participation difficult or unsafe.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00260481

Locations
United States, California
UCLA Integrated Substance Abuse Programs
Los Angeles, California, United States, 90025
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: Walter Ling, M.D. UCLA Integrated Substance ABuse Programs
  More Information

No publications provided by University of California, Los Angeles

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Walter Ling, Principal Investigator, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00260481     History of Changes
Other Study ID Numbers: 05-01-076-01
Study First Received: November 29, 2005
Last Updated: January 28, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Los Angeles:
Methamphetamine Dependence
Pharmacotherapy

Additional relevant MeSH terms:
Substance-Related Disorders
Mental Disorders
Methamphetamine
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors

ClinicalTrials.gov processed this record on July 23, 2014